<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Rani Therapeutics Holdings Inc — News on 6ix</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc</link>
<description>Latest news and press releases for Rani Therapeutics Holdings Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/rani-therapeutics-holdings-inc" rel="self" type="application/rss+xml" />
<item>
<title>Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-appoints-dr-sara-kenkare-mitra-as-strategic-advisor-to-advance-platform-and-clinical-strategy</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-appoints-dr-sara-kenkare-mitra-as-strategic-advisor-to-advance-platform-and-clinical-strategy</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage</description>
</item>
<item>
<title>Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-provides-corporate-update</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed</description>
</item>
<item>
<title>Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-appoints-jesper-hoiland-as-head-of-strategy-to-advance-corporate-and-pipeline-prioritization</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-appoints-jesper-hoiland-as-head-of-strategy-to-advance-corporate-and-pipeline-prioritization</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage</description>
</item>
<item>
<title>Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 19 Mar 2026 20:05:00 GMT</pubDate>
<description>SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025 and provide a business update on Thursday, March 26, 2026 after the close of trading. Rani’s management team will host a conference call and webcast beg</description>
</item>
<item>
<title>Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-promotion-alireza-120000680</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-promotion-alireza-120000680</guid>
<pubDate>Wed, 28 Jan 2026 12:00:00 GMT</pubDate>
<description>SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. “We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase</description>
</item>
<item>
<title>Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-initiates-phase-1-120000863</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-initiates-phase-1-120000863</guid>
<pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
<description>- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus subcutaneous injection - SAN JOSE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation of a Phase 1 clinical trial</description>
</item>
<item>
<title>Rani Therapeutics to Participate in the Evercore Healthcare Conference</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-participate-evercore-healthcare-210500268</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-participate-evercore-healthcare-210500268</guid>
<pubDate>Mon, 24 Nov 2025 21:05:00 GMT</pubDate>
<description>SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in the upcoming Evercore Healthcare Conference. Details below: 8th Annual Evercore Healthcare ConferenceDate: Wednesday, December 3, 2025 at 8:45 am E.T.Location: Coral Gables, FLPresenter: Chief Executive</description>
</item>
<item>
<title>Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-reports-third-quarter-213000408</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-reports-third-quarter-213000408</guid>
<pubDate>Thu, 06 Nov 2025 21:30:00 GMT</pubDate>
<description>– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus – – Appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the Board of Directors – – Cash runway expected to extend into 2028 – SAN JOSE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings</description>
</item>
<item>
<title>Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-present-preclinical-data-120000333</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-present-preclinical-data-120000333</guid>
<pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
<description>SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule, the company’s oral delivery platform, at ObesityWeek® 2025 taking place both virtually and in-person on November 4-7, 2025 in Atlanta, Georgia. Details of the presentation are as follows: Abstr</description>
</item>
<item>
<title>Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-appointments-abe-200500611</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-appointments-abe-200500611</guid>
<pubDate>Thu, 23 Oct 2025 20:05:00 GMT</pubDate>
<description>SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Abraham (“Abe”) Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. In conjunction with the new appointments, Andrew Farquharson and Maulik Nanavaty have stepped down from the Board of Directors. “We are thrilled to welcome Abe a</description>
</item>
<item>
<title>Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-closing-oversubscribed-200100472</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-closing-oversubscribed-200100472</guid>
<pubDate>Thu, 23 Oct 2025 20:01:00 GMT</pubDate>
<description>Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran Each of Samsara and Anomaly has the right to designate one member of the Company’s board of directors SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of</description>
</item>
<item>
<title>Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-oversubscribed-60-113100030</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-oversubscribed-60-113100030</guid>
<pubDate>Fri, 17 Oct 2025 11:31:00 GMT</pubDate>
<description>Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir ImranAt the closing of the financing, each of Samsara and Anomaly will have the right to designate one member of the Company’s board of directors SAN JOSE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics co</description>
</item>
<item>
<title>Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-1-085-113000440</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-1-085-113000440</guid>
<pubDate>Fri, 17 Oct 2025 11:30:00 GMT</pubDate>
<description>Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit royalties on product sales for the first license agreementChugai has the option to extend its rights to partner with Rani on up to 5 additional drug targets at similar deal terms bringing the total potential deal value to over $1 billionRani announced a $60.3 million private placement financing led by</description>
</item>
<item>
<title>Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-reports-second-quarter-200500453</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-reports-second-quarter-200500453</guid>
<pubDate>Thu, 07 Aug 2025 20:05:00 GMT</pubDate>
<description>– Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to subcutaneous delivery at ENDO 2025 – – Phase 1 study for RT-114 for the treatment of obesity expected to initiate in the second half of 2025 – – Announced a warrant inducement transaction with an existing investor with gross proceeds of $4.3 million –</description>
</item>
<item>
<title>Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-holdings-inc-announces-130000039</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-holdings-inc-announces-130000039</guid>
<pubDate>Tue, 15 Jul 2025 13:00:00 GMT</pubDate>
<description>SAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 4,354,000 shares of Rani Therapeutics’ Class A common stock at a purchase price of $0.40 per share and pre-funded warrants to purchase</description>
</item>
<item>
<title>Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-progen-announce-breaking-090000107</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-progen-announce-breaking-090000107</guid>
<pubDate>Mon, 14 Jul 2025 09:00:00 GMT</pubDate>
<description>SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. Details of the presentations are as follows: Abstract Title: Oral Delivery of a Bispecific GLP</description>
</item>
<item>
<title>Rani Therapeutics Announces Research Agreement with Chugai</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-research-agreement-120000895</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-research-agreement-120000895</guid>
<pubDate>Mon, 19 May 2025 12:00:00 GMT</pubDate>
<description>- Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company has entered into a Research Agreement on 13th August, 2024, for two molecules with undisclosed targets</description>
</item>
<item>
<title>Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-reports-first-quarter-200500348</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-reports-first-quarter-200500348</guid>
<pubDate>Tue, 13 May 2025 20:05:00 GMT</pubDate>
<description>- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Phase 1 study for RT-114 for the treatment of obesity expected to initiate in mid-2025 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani</description>
</item>
<item>
<title>Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-reports-fourth-quarter-200500296</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-reports-fourth-quarter-200500296</guid>
<pubDate>Mon, 31 Mar 2025 20:05:00 GMT</pubDate>
<description>- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - - Preclinical data of four incretin-based molecules underscores the RaniPill® platform's potential to facilitate the oral delivery of a diverse array of obesity treatments - - Phase 1 study for RT-</description>
</item>
<item>
<title>Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102</title>
<link>https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-preclinical-data-200500857</link>
<guid isPermaLink="true">https://6ix.com/company/rani-therapeutics-holdings-inc/news/rani-therapeutics-announces-preclinical-data-200500857</guid>
<pubDate>Wed, 26 Mar 2025 20:05:00 GMT</pubDate>
<description>- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence – - Both groups demonstrated comparable weight loss with less variability observed with RT-114 compared to subcutaneous PG-102 – - Phase 1 clinical trial of subcutaneous PG-102 demonstrated weight loss in obese patients, with an average reduction of 4.8% and up to 8.7% following five weeks of dosing - - Data bols</description>
</item>
</channel>
</rss>